Document Detail


Varenicline and cardiovascular adverse events: a perspective review.
MedLine Citation:
PMID:  25083271     Owner:  NLM     Status:  PubMed-not-MEDLINE    
Abstract/OtherAbstract:
Smoking is a leading preventable cause of mortality and morbidity. Varenicline, a first-line smoking cessation aid, is used widely to achieve successful quit rates in smokers. A number of studies and systematic reviews have evaluated the safety profile of the drug. To date, three systematic reviews by Singh and colleagues, Prochaska and Hilton, and Ware and colleagues, published between 2011 and 2013, have evaluated serious cardiovascular adverse events with varenicline use. Even though all three reviews demonstrated that serious cardiovascular adverse events were nominally more frequent in varenicline-treated patients when compared with placebo, a significantly increased event rate was found only in the review by Singh and colleagues. The three reviews included similar trials but differed in the evaluation of outcomes and performance of summary statistic computation. Though the evidence from the two most recent systematic reviews demonstrated that risk of serious cardiovascular events might not be increased with varenicline use, the US Food and Drug Administration has advised prescription with caution combined with close monitoring and education of patients until more conclusive evidence is available. Results of these reviews cannot be generalized to patients with unstable cardiac conditions.
Authors:
Yohalakshmi Chelladurai; Sonal Singh
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Therapeutic advances in drug safety     Volume:  5     ISSN:  2042-0986     ISO Abbreviation:  Ther Adv Drug Saf     Publication Date:  2014 Aug 
Date Detail:
Created Date:  2014-08-01     Completed Date:  2014-08-01     Revised Date:  2014-08-15    
Medline Journal Info:
Nlm Unique ID:  101549074     Medline TA:  Ther Adv Drug Saf     Country:  England    
Other Details:
Languages:  eng     Pagination:  167-72     Citation Subset:  -    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Cardiovascular toxicity associated with adjuvant trastuzumab therapy: prevalence, patient characteri...
Next Document:  Adjuvant valproate therapy for patients with suspected mixed-depressive features.